In conclusion, this research demonstrated a synergistic interaction between MYC-driven cell cycle progression and trametinib-induced MEK inhibition, enhancing HNSCC sensitivity to DNA damage and apoptotic cell death. This evidence concerns the gene MAP2K7 and head and neck squamous cell carcinoma.